FSD Pharma Overview
Latest P/E ratio for FSD Pharma: -0.15 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.15
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
FSD Pharma (HUGE) currently reports a P/E ratio of -0.15. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore FSD Pharma's P/E ratio history and peer comparisons.
FSD Pharma's P/E ratio of -0.15 is lower than the Healthcare sector average of 25.3. That is roughly 100.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates FSD Pharma's market price to a fundamental measure such as earnings, sales, or book value. At -0.15, HUGE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.15, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for FSD Pharma, and consider following HUGE for alerts when major investors trade the stock.
FSD Pharma is classified in the Healthcare sector. On P/E ratio, it currently shows -0.15 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HUGE with unrelated industries.
